Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Size Is Rewarded When Fostering Brand In India, But Pricing Has To Be Right: Elsevier Business Intelligence Webinar

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - Becoming too big may have resulted in operational inefficiencies and deteriorating R&D output for global drug makers, but getting bigger may be a successful formula for branded generics businesses in emerging markets

You may also be interested in...

CASE STUDY: Can Novartis India Reboot Star Brand Voveran?

Faced with savvy competitor introductions and government price cuts, Voveran, a star painkiller brand from Novartis, is seeing unprecedented market challenges in India. Can it survive the onslaught and what is the company doing to revive the product?

Emerging Markets Survey Shows Limited Premium For International Drug Brands-Credit Suisse

A recent Credit Suisse report showed acceptability for global brands widely varied in emerging markets. While consumers did not show a great degree of trust for local pharmaceutical brands, the premium they are willing to pay for an international brand is also limited.

Closer Look: Sun-Ranbaxy A Powerhouse But Sales Culture A Dilemma?

The merger of Sun and Ranbaxy is seen as the most ideal combination to seize Indian market opportunities. But field force integration may pose a tough barrier as the two sides operate very different marketing strategies.

Related Content

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts